Register to get unlimited Level 2

Company Announcements

Director/PDMR Shareholding

Related Companies

By LSE RNS

RNS Number : 7672I
Consort Medical PLC
21 June 2017
 

Consort Medical plc

Director Shareholding

21 June 2017

 

Consort Medical plc (the 'Company') announces that Paul Hayes, Chief Financial Officer purchased 4,000 ordinary 10p shares at a price of £10.9445 per share on 20 June 2017. Following this transaction Mr Hayes holds 8,000 ordinary shares in the Company.

The Notification of Dealing Form set out below is provided in accordance with the requirements of the Market Abuse Regulation.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Paul Hayes

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Consort Medical plc

 

b)

 

LEI

 

 

2138001TBP74FD66QT38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 10p each



Identification code

ISIN: GB0000946276



b)

 

Nature of the transaction

 

 

Acquisition

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




£10.9445

4,000







d)

 

Aggregated information



n/a single transaction

- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

2017-06-20

f)

 

Place of the transaction

 

 

London Stock Exchange Main Market (XLon)

 

Enquiries: Michelle Palmer, Assistant Company Secretary 01442 8867920

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.  

Our businesses  

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com. 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFFLFLDQFBBBK

Top of Page